We represented axialHealthcare, a care optimization platform navigating substance use issues for patients, providers, and health plans, in a $15 million Series C round of financing to accelerate its expansion into the substance use disorder (SUD) treatment, and recovery sector. Previous institutional investors Oak HC/FT, .406 Ventures, BlueCross BlueShield Venture Partners (BCBSVP), and Sandbox Advantage Fund led the round.
axialHealthcare Closes Series C Funding Round
You Also May Be Interested In:
Representation of Twin River Worldwide Holdings, Inc. (NYSE: TRWH) in its definitive agreement to acquire Jumer’s Casino & Hotel, from Delaware North Companies Gaming & Entertainment, Inc., for $120 million in cash
Representation of Southern Ear, Nose, and Throat and Allergy (SENTA) Partners, an ENT and allergy management services organization backed by Shore Capital Partners, in its affiliation with Atlanta Allergy & Asthma, the largest allergy practice in Georgia
Representation of Truxton Trust, a subsidiary of financial holding company, Truxton Corporation (OTCPK: TRUX), in the sale of $15 million aggregate principal amount of fixed-to-floating rate subordinated notes due in 2030